Nordicus Partners Corporation NORD
3.73 USD -0.38 (-9.15%)
At closeNov 4, 2026, 4:00 PM EST
3.72 0.00 -0.13%
After hours · Nov 4, 4:00 PM ET
3.51 Day range 4.00
1.48 52-week range 5.15
- YTD
- -25.50%
- 1 year
- -25.50%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million. Gelteq (NASDAQ:GELS)…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
benzinga.com Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.
globenewswire.com Nordicus Partners Corporation Announces Uplisting to The Nasdaq Capital Market BEVERLY HILLS, California, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a biotech company specializing in developing breakthrough…
globenewswire.com Nordicus Partners Corporation Appoints Elizabeth Addonizio to Its Board of Directors Appointment strengthens board independence and financial expertise as Company advances its clinical pipeline. BEVERLY HILLS, California, Sept.
defenseworld.net Nordicus Partners Corp (OTCMKTS:NORD) Short Interest Up 757.6% in July Nordicus Partners Corp (OTCMKTS:NORD - Get Free Report) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 283 shares, an increase…
globenewswire.com Nordicus Partners Corporation Corporate Update Orocidin's QR-01 demonstrates efficacy in two preclinical periodontitis models; micro-CT confirms reduced bone loss Phase IIa clinical trial in patients planned H1 2027 at the University of…
globenewswire.com Nordicus Partners Corporation Corporate Update BEVERLY HILLS, California, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting…
thenewswire.com Nordique Announces Change in CEO and Director Vancouver, British Columbia – TheNewswire - January 29, 2026 – Nordique Resources Inc. (CSE: NORD) (the “Company” or “Nordique ”) is pleased to announce that James Hocking has been appointed as a…
globenewswire.com NoviThera has initiated the first efficacy animal studies BEVERLY HILLS, California, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NoviThera ApS (“NoviThera”), a majority owned subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a…
globenewswire.com Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats. BEVERLY HILLS, California, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial…
globenewswire.com Orocidin develops novel cGMP manufacturing process in collaboration with Syngene The partnership addressed complex peptide synthesis and purification challenges to achieve high yield and purity suitable for clinical use BEVERLY HILLS, California, Oct. 20, 2025 (GLOBE NEWSWIRE) --…
globenewswire.com Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS BEVERLY HILLS, California, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting…
benzinga.com Nordicus Partners Files To Uplist Common Stock To Nasdaq Capital Market Nordicus Partners Corporation (OTCQB:NORD) ("Nordicus" or the "Company"), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves…
globenewswire.com Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market BEVERLY HILLS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S.…
globenewswire.com Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors Beverly Hills, California, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a business accelerator and holding company specializing in…
globenewswire.com Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia BEVERLY HILLS, California, April 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert A/S (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial…
globenewswire.com Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in Dogs BEVERLY HILLS, California, April 02, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial…
globenewswire.com Orocidin and Syngene Partner to Accelerate Biotech Innovation BEVERLY HILLS, California, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial…
globenewswire.com Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial…
globenewswire.com Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial…
globenewswire.com Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment BEVERLY HILLS, California, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company…
globenewswire.com Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin's Breakthrough Treatment for Periodontitis BEVERLY HILLS, California, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting…